By Karlee Weinmann ( May 24, 2013, 1:36 PM EDT) -- Eye care product company Bausch & Lomb Inc. is closing in on a deal to sell itself to Valeant Pharmaceuticals International Inc. for $9 billion, according to a Friday report from the Wall Street Journal. The deal would be a landmark purchase for Valeant, which shelved plans in April to buy another drugmaker, Actavis Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.